Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax.

ABSTRACT: Bacillus anthracis is a Gram-positive Centers for Disease Control and Prevention category "A" biothreat pathogen. Without early treatment, inhalation of anthrax spores with progression to inhalational anthrax disease is associated with high fatality rates. Gepotidacin is a novel first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and is being evaluated for use against biothreat and conventional pathogens. Gepotidacin selectively inhibits bacterial DNA replication via a unique binding mode and has in vitro activity against a collection of B. anthracis isolates including antibacterial-resistant strains, with the MIC₉₀ ranging from 0.5 to 1 µg/mL. In vivo activity of gepotidacin was als

SUBMITTER: Hilliard JJ 

PROVIDER: S-EPMC10916377 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature